Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of LY01610 versus topotecan in relapsed small cell lung cancer
CTR20234323Phase 3Active
- Sponsor
- Luye Pharma Group
- Start
- Mar 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of irinotecan liposome, topotecan in small cell lung cancer (SCLC), sponsored by Luye Pharma Group. Started Mar 2024; status: active.
02
Drugs
irinotecan liposometopotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20234323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234323.